Akio Niimi is an expert in Pulmonology at Nagoya City University (Japan). As of October 2026, ScienceLeadR ranks Akio Niimi in the top 1% of experts worldwide for Cough-Variant Asthma, Cough and Respiration Disorders. Akio Niimi has authored 375 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 1,256 (community average: 125). How the SLR is computed.

LeadR Profile

Akio Niimi Nagoya City University Japan
1 256 ScienceLeadR Reputation 1256
Network Map

Pulmonology

Subspecialties: Immunology - Oncology - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1999 - 2026

Source: PubMed

Nagoya City University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 375

Citations

Citations: 9 362 1st author: 22 Last author: 147 Unique author: 25


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Increased Lymphocyte Proportions as a Candidate Biomarker for Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitors and Chemotherapy.
PMID 42834599 — lymphocytes, neoplasms, drug therapy, biomarkers, drug-related side effects and adverse reactions, immune checkpoint inhibitors, therapeutics, chemotherapy
Cancer Med20260
Impact of Cardiovascular Comorbidities on Clinical Outcomes Across the Asthma Spectrum.
PMID 42764581 — comorbidity, monocytes, cardiovascular diseases, asthma
Respirology20260
Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.
PMID 42638984 — therapeutics, asthma
J Asthma Allergy20260
Oesophageal functional phenotypes in refractory gastro-oesophageal reflux disease-related chronic cough.
PMID 42267362 — phenotype, cough, gastroesophageal reflux, chronic cough
ERJ Open Res20260
Risk Factors for COVID-19 mRNA Vaccine-Associated Exacerbations in Patients With Obstructive Airway Diseases: REsearch for Asthma and COPD ExacerbaTION Caused by COVID-19 mRNA Vaccination (REACTION Study).
PMID 42223036 — vaccines, rna, messenger, vaccination, pulmonary disease, chronic obstructive, covid-19, risk factors, research, asthma
Allergy Asthma Immunol Res20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 2
Phase 3 1

By status:

Completed 3

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 3

Main Topics

LeadR Networks

Main global connection map